CSPC Pharmaceutical Group Ltd. has announced its unaudited consolidated results for the three months ended 31 March 2025. The company reported a revenue of RMB5.5 billion from its finished drugs business, marking a 27.3% decrease compared to the same period last year. This decline is primarily attributed to the ongoing impact of industry policies, such as centralised volume-based procurement of drugs and price adjustments for drugs included in the National Reimbursement Drug List. Revenue from the nervous system therapeutic area also saw a significant drop, decreasing by 29.5% to RMB1.9 billion. Despite these challenges, the company continues to navigate the effects of policy changes on its product sales. The financial data presented is based on the internal records and management accounts of the Group for the specified period. Further details on the company's financial performance can be accessed in the full quarterly results announcement. The company did not provide specific guidance or outlook for future periods.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.